Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 9;24(8):6961.
doi: 10.3390/ijms24086961.

How Can We Prevent Mother-to-Child Transmission of HTLV-1?

Affiliations
Review

How Can We Prevent Mother-to-Child Transmission of HTLV-1?

Kazuo Itabashi et al. Int J Mol Sci. .

Abstract

The perception of human T-cell leukemia virus type 1 (HTlV-1) infection as a "silent disease" has recently given way to concern that its presence may be having a variety of effects. HTLV-1 is known to cause adult T-cell leukemia (ATL), an aggressive cancer of peripheral CD4 T cells; however, it is also responsible for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Most patients develop ATL as a result of HTLV-1 mother-to-child transmission. The primary route of mother-to-child transmission is through the mother's milk. In the absence of effective drug therapy, total artificial nutrition such as exclusive formula feeding is a reliable means of preventing mother-to-child transmission after birth, except for a small percentage of prenatal infections. A recent study found that the rate of mother-to-child transmission with short-term breastfeeding (within 90 days) did not exceed that of total artificial nutrition. Because these preventive measures are in exchange for the benefits of breastfeeding, clinical applications of antiretroviral drugs and immunotherapy with vaccines and neutralizing antibodies are urgently needed.

Keywords: adult T-cell leukemia (ATL); antenatal screening; human T-cell leukemia virus type 1 (HTlV-1); mother-to-child transmission; nutritional regimens; prevention.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest associated with this manuscript.

Figures

Figure 1
Figure 1
Risk factors associated with development of HTLV-1 mother-to-child transmission. Risk factors for mother-to-child transmission are broadly classified as long-term breastfeeding, high PVL in carrier mothers, HLA class type 1 concordance between mother and child, and mothers with untested HTLV-1 antibodies. HLA, human leukocyte antigen.
Figure 2
Figure 2
Forest plot of the risk ratios of HTLV-1 MTCT in the STBF ≤ 3 months group compared with that of the ExFF group. There is no statistical difference in the risk of MTCT between the two groups (pooled risk ratio (RR): 0.72, 95% CI: 0.30–1.77). Abbreviations: STBF, short-term breastfeeding; ExFF, exclusive formula feeding; M–H, Mantel–Haenszel; CI, confidence interval; RR, risk ratio; MTCT, mother-to-child transmission; events, number of cases with mother-to-child transmission; total, number of children born to carrier mothers; weight, influence of studies on overall meta-analysis. The figure is reproduced from Miyazawa et al. [103].
Figure 3
Figure 3
Forest plot of the risk ratios of HTLV-1 MTCT in the STBF ≤ 6 months group compared with that of the ExFF group. Comparing STBF ≤ 6 months and ExFF showed that STBF ≤ 6 months was associated with an approximately 3-fold higher risk of MTCT than that of ExFF (pooled RR: 2.91, 95% CI: 1.69–5.03). Abbreviations: STBF, short-term breastfeeding; ExFF, exclusive formula feeding; M–H, Mantel–Haenszel; CI, confidence interval; RR, risk ratio; MTCT, mother-to-child transmission; events, number of cases with mother-to-child transmission; total, number of children born to carrier mothers; weight, influence of studies on overall meta-analysis. The figure is reproduced from Miyazawa et al. [103].
Figure 4
Figure 4
Algorithm for diagnosing HTLV-1 infection in Japan. Currently, no confirmatory tests using Western blotting are conducted in Japan. Flowchart for identifying HTLV-1 carriers among pregnant women. CLEIA, chemiluminescent enzyme immunoassay; CLIA, chemiluminescent immunoassay; ECLIA, electrochemiluminescent immunoassay; PA, particle agglutination; WB, Western blotting; LIA, line immunoassay; PCR, polymerase chain reaction. The figure is reproduced from Itabashi et al. [54]. For further details, please refer to Okuma et al. [129].

Similar articles

Cited by

References

    1. Moore P.S., Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer. 2010;10:878–889. doi: 10.1038/nrc2961. - DOI - PMC - PubMed
    1. Gallo R.C. Kyoto Workshop on some specific recent advances in human tumor virology. Cancer Res. 1981;41:4738–4739. - PubMed
    1. Hinuma Y., Nagata K., Hanaoka M., Nakai M., Matsumoto T., Kinoshita K., Shirakawa S., Miyoshi I. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. USA. 1981;78:6476–6480. doi: 10.1073/pnas.78.10.6476. - DOI - PMC - PubMed
    1. Gessain A., Vernant J., Maurs L., Barin F., Gout O., Calender A., De Thé G. Antibodies to human t-lymphotropic virus type-i in patients with tropical spastic paraparesis. Lancet. 1985;326:407–410. doi: 10.1016/S0140-6736(85)92734-5. - DOI - PubMed
    1. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., Matsumoto M., Tara M. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986;1:1031–1032. doi: 10.1016/S0140-6736(86)91298-5. - DOI - PubMed

MeSH terms